Transcription of IN THIS ISSUE
{{id}} {{{paragraph}}}
1 IN THIS ISSUE Biosimilar Preferred Product Established for Rituximab .. 4 Guidelines Established for Avalglucosidase alfa-ngpt (Nexviazyme) .. 4 Biosimilar Preferred Products Established for Pegfilgrastim .. 5 Guidelines Established for Eculizumab (Soliris) .. 5 Coverage Guidelines Revised for Brentuximab Vedotin (Adcetris) .. 5 Coverage Guidelines Revised for Parathyroid Hormone (Natpara) .. 7 Policy Established for Anifrolumab-fnia (Saphnelo) .. 8 New Criteria for Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors .. 8 Established New Criteria for Eustachian Tube Balloon Dilation .. 9 Revised and Established New Criteria for Pain Management of Peripheral Nerves by Injection .. 10 Medicare Advantage .. 12 Biosimilar Preferred Product Established for Rituximab .. 12 Biosimilar Preferred Products Established for Pegfilgrastim .. 12 Guidelines Established for Eculizumab (Soliris).
Highmark Blue Shield has established preferred product for rituximab. The preferred product for rheumatoid arthritis (RA) indications is rituximab- pvvr (Ruxience) when the clinical criteria within the policy are met. This revised Medical Policy will apply to professional providers and facility claims. The effective date is April 1, 2022.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}